Daratumumab plus bortezomib, melphalan, and prednisone in East Asian patients with non-transplant multiple myeloma: subanalysis of the randomized phase 3 ALCYONE trial

In the ALCYONE trial, daratumumab plus bortezomib, melphalan, and prednisone (D-VMP) reduced the risk of disease progression or death by 50% versus bortezomib, melphalan, and prednisone (VMP) in patients with transplant-ineligible newly diagnosed multiple myeloma. Here, we report a subanalysis of Ea...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujisaki, Tomoaki, Ishikawa, Takayuki, Takamatsu, Hiroyuki, Suzuki, Kenshi, Min, Chang-Ki, Lee, Jae Hoon, Wang, Jianping, Carson, Robin, Crist, Wendy, Qi, Ming, Nagafuji, Koji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6900260/
https://www.ncbi.nlm.nih.gov/pubmed/31620815
http://dx.doi.org/10.1007/s00277-019-03794-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6900260/
https://www.ncbi.nlm.nih.gov/pubmed/31620815
http://dx.doi.org/10.1007/s00277-019-03794-9

Ejemplares similares